{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T16:22:37Z","timestamp":1781108557977,"version":"3.54.1"},"reference-count":112,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Polish Ministry of Health subvention","award":["SUBZ.A020.23.068"],"award-info":[{"award-number":["SUBZ.A020.23.068"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Allergic diseases triggered by airborne allergens such as allergic rhinitis and conjunctivitis are increasingly prevalent, posing significant challenges for both patients and healthcare systems. Assessing the efficacy of allergen immunotherapy and other anti-allergic treatments requires precise and reproducible methods. Allergen exposure chambers (AECs) have emerged as advanced tools for evaluating clinical outcomes, offering controlled conditions that address many limitations of traditional field-based studies. This review explores the advantages of AECs in allergy management, emphasizing their role in providing standardized allergen exposure for both clinical research and routine assessments. AECs deliver consistent and reproducible data comparable to the nasal allergen challenge and natural allergen exposure, making them a valuable addition to the diagnosis and treatment effectiveness of allergic diseases. Although they are well suited to early-stage clinical trials, further standardization and validation are needed to gain broader acceptance in pivotal phase III studies. Future research should focus on refining AEC protocols and integrating them into regulatory frameworks, ensuring their role in the advancement of therapeutic approaches for allergic diseases.<\/jats:p>","DOI":"10.3390\/jcm13237268","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T08:24:14Z","timestamp":1732868654000},"page":"7268","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Modern Approach to Clinical Outcome Assessment in Allergy Management: Advantages of Allergen Exposure Chambers"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7201-8638","authenticated-orcid":false,"given":"Magdalena","family":"Zemelka-Wiacek","sequence":"first","affiliation":[{"name":"Department of Clinical Immunology, Faculty of Medicine, Wroclaw Medical University, 50-367 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaci.2019.06.049","article-title":"Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence","volume":"145","author":"Bousquet","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"De Carli, M., Capezzali, E., Tonon, S., and Frossi, B. (2023). Mechanism and clinical evidence of immunotherapy in allergic rhinitis. Front. Allergy, 4.","DOI":"10.3389\/falgy.2023.1217388"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.jaci.2022.10.007","article-title":"Immunotherapy: State-of-the-art review of therapies and theratypes","volume":"150","author":"Agache","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaip.2023.11.027","article-title":"Mechanisms and Predictive Biomarkers of Allergen Immunotherapy in the Clinic","volume":"12","author":"Layhadi","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/all.15945","article-title":"Hot topics in allergen immunotherapy, 2023: Current status and future perspective","volume":"79","author":"Agache","year":"2024","journal-title":"Allergy"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.5414\/ALX02379E","article-title":"AIT 2023: Current innovation and future outlook","volume":"7","author":"Jutel","year":"2023","journal-title":"Allergol. Sel."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jaci.2014.10.045","article-title":"Environmental exposure chambers in allergen immunotherapy trials: Current status and clinical validation needs","volume":"135","author":"Kaul","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/all.13133","article-title":"Allergen exposure chambers: Harmonizing current concepts and projecting the needs for the future\u2014An EAACI Position Paper","volume":"72","author":"Pfaar","year":"2017","journal-title":"Allergy"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1111\/all.15755","article-title":"The One Health approach for allergic diseases and asthma","volume":"78","author":"Jutel","year":"2023","journal-title":"Allergy"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1081-1206(10)62616-6","article-title":"Environmental exposure unit: A system to test anti-allergic treatment","volume":"83","author":"Day","year":"1999","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/ACI.0b013e328360c7b6","article-title":"Are results of environmental exposure units transferable to real-life exposure?","volume":"13","author":"Zieglmayer","year":"2013","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.anai.2014.11.006","article-title":"Responsiveness to timothy grass pollen in individuals without known natural exposure in an allergen challenge chamber","volume":"114","author":"Ramirez","year":"2015","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.jaci.2014.09.047","article-title":"Symptom dynamics during repeated serial allergen challenge chamber exposures to house dust mite","volume":"135","author":"Jacobs","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1111\/all.14957","article-title":"Technical standards in allergen exposure chambers worldwide\u2014An EAACI Task Force Report","volume":"76","author":"Pfaar","year":"2021","journal-title":"Allergy"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11882-020-00922-8","article-title":"Utility of Environmental Exposure Unit Challenge Protocols for the Study of Allergic Rhinitis Therapies","volume":"20","author":"Hossenbaccus","year":"2020","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.anai.2013.07.019","article-title":"Environmental exposure unit: A sensitive, specific, and reproducible methodology for allergen challenge","volume":"111","author":"Ellis","year":"2013","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11882-015-0514-4","article-title":"Controlled Allergen Challenge Facilities and Their Unique Contributions to Allergic Rhinitis Research","volume":"15","author":"North","year":"2015","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2332\/allergolint.13-OA-0578","article-title":"Characteristics of the Chiba environmental challenge chamber","volume":"63","author":"Hamasaki","year":"2014","journal-title":"Allergol. Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.anai.2011.04.009","article-title":"Validation of the Biogenics Research Chamber for Juniperus ashei (mountain cedar) pollen. Ann","volume":"107","author":"Jacobs","year":"2011","journal-title":"Allergy Asthma Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.anai.2010.01.012","article-title":"Factors that affect the allergic rhinitis response to ragweed allergen exposure. Ann","volume":"104","author":"Ellis","year":"2010","journal-title":"Allergy Asthma Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1111\/j.1365-2222.2003.01810.x","article-title":"Validation of an environmental exposure unit for controlled human inhalation studies with grass pollen in patients with seasonal allergic rhinitis","volume":"33","author":"Krug","year":"2003","journal-title":"Clin. Exp. Allergy"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/iid3.143","article-title":"Technical and clinical validation of the Allergen BioCube\u00ae for timothy grass","volume":"5","author":"Angjeli","year":"2017","journal-title":"Immun. Inflamm. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/cea.12747","article-title":"Method for a homogeneous distribution of pollens in an environmental exposure chamber","volume":"46","author":"Kenney","year":"2016","journal-title":"Clin. Exp. Allergy"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13223-015-0071-3","article-title":"Clinical validation of controlled grass pollen challenge in the Environmental Exposure Unit (EEU)","volume":"11","author":"Ellis","year":"2015","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_25","first-page":"64801","article-title":"Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber","volume":"193","author":"Kosowska","year":"2023","journal-title":"J. Vis. Exp."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/cea.14485","article-title":"Rhinoconjunctivitis severity induced by cat exposure influences early and late asthmatic responses: Evidence from an environmental exposure chamber","volume":"54","author":"Piotin","year":"2024","journal-title":"Clin. Exp. Allergy"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1159\/000531878","article-title":"Sodium Chloride versus Lactose as a Carrier for House Dust Mite Allergen in Allergen Chamber Studies: A Clinical Study to Assess Noninferiority","volume":"184","author":"Dieter","year":"2023","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5414\/CPP47071","article-title":"A combination of cetirizine and pseudoephedrine has therapeutic benefits when compared to single drug treatment in allergic rhinitis","volume":"47","author":"Badorrek","year":"2009","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S0091-6749(98)70172-1","article-title":"Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: Effects after controlled ragweed pollen challenge in an environmental exposure unit","volume":"101","author":"Day","year":"1998","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1111\/all.15199","article-title":"Development and validation of combined symptom-medication scores for allergic rhinitis","volume":"77","author":"Azevedo","year":"2022","journal-title":"Allergy"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/all.15485","article-title":"Validated allergen exposure chamber is a plausible tool for the assessment of house dust mite-triggered allergic rhinitis","volume":"78","author":"Kosowska","year":"2023","journal-title":"Allergy"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/cea.14482","article-title":"Clinical validation of grass pollen exposure chamber in patients with allergic rhinitis triggered by timothy grass","volume":"54","author":"Kosowska","year":"2024","journal-title":"Clin. Exp. Allergy"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1067\/mai.2000.104550","article-title":"Onset of action of intranasal budesonide (Rhinocort Aqua) in seasonal allergic rhinitis studied in a controlled exposure model","volume":"105","author":"Day","year":"2000","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/JAA.S150251","article-title":"Iodixanol nasal solution reduces allergic rhinoconjunctivitis signs and symptoms in Allergen BioCube\u00ae: A randomized clinical trial","volume":"12","author":"Gomes","year":"2019","journal-title":"J. Asthma Allergy"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13223-021-00536-3","article-title":"Clinical validation of controlled exposure to house dust mite in the Environmental Exposure Unit (EEU)","volume":"17","author":"Hossenbaccus","year":"2021","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13601-017-0169-4","article-title":"Peak nasal inspiratory flow as outcome for provocation studies in allergen exposure chambers: A GA2LEN study","volume":"7","author":"Boelke","year":"2017","journal-title":"Clin. Transl. Allergy"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"100494","DOI":"10.1016\/j.waojou.2020.100494","article-title":"First evaluation of a symbiotic food supplement in an allergen exposure chamber in birch pollen allergic patients","volume":"14","author":"Bergmann","year":"2020","journal-title":"World Allergy Organ J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jaci.2020.02.024","article-title":"Nasal allergen challenge and environmental exposure chamber challenge: A randomized trial comparing clinical and biological responses to cat allergen","volume":"145","author":"Larson","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S0091-6749(97)80014-0","article-title":"Determinants of airway responses to cat allergen: Comparison of environmental challenge to quantitative nasal and bronchial allergen challenge","volume":"99","author":"Sicherer","year":"1997","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.anai.2018.02.003","article-title":"Lack of effect of Timothy grass pollen sublingual immunotherapy tablet on birch pollen-induced allergic rhinoconjunctivitis in an environmental exposure unit","volume":"120","author":"Ellis","year":"2018","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/cea.14087","article-title":"Cat allergen exposure in a naturalistic exposure chamber: A prospective observational study in cat-allergic subjects","volume":"52","author":"Yang","year":"2022","journal-title":"Clin. Exp. Allergy"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000526423","article-title":"Efficacy and safety of a drug-free, barrier-forming nasal spray for allergic rhinitis: Randomized, open-label, crossover noninferiority trial","volume":"184","author":"Nehrig","year":"2023","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jaci.2016.03.039","article-title":"Efficacy and safety of sublingual tablets of house dust mite allergen extracts: Results of a dose-ranging study in an environmental exposure chamber","volume":"138","author":"Roux","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jaci.2016.12.986","article-title":"Clinical validation of a house dust mite environmental challenge chamber model","volume":"140","author":"Zieglmayer","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2147\/JAA.S123547","article-title":"Technical and clinical validation of an environmental exposure unit for ragweed","volume":"9","author":"Gomes","year":"2016","journal-title":"J. Asthma Allergy"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000189197","article-title":"Validation study of the OHIO Chamber in patients with Japanese cedar pollinosis","volume":"149","author":"Hashiguchi","year":"2009","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13223-016-0156-7","article-title":"Clinical validation of controlled exposure to birch pollen in the Environmental Exposure Unit (EEU)","volume":"12","author":"Ellis","year":"2016","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1111\/all.12947","article-title":"Safety, efficacy and repeatability of a novel house dust mite allergen challenge technique in the Fraunhofer allergen challenge chamber","volume":"71","author":"Lueer","year":"2016","journal-title":"Allergy"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2332\/allergolint.O-06-453","article-title":"Preliminary study on Japanese cedar pollinosis in an artificial exposure chamber (OHIO Chamber)","volume":"56","author":"Hashiguchi","year":"2007","journal-title":"Allergol. Int."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.anl.2010.04.001","article-title":"Preliminary study of a challenge test to the patients with Japanese cedar pollinosis using an environmental exposure unit","volume":"37","author":"Ito","year":"2010","journal-title":"Auris Nasus Larynx"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.jaci.2016.08.025","article-title":"Validation of the Global Allergy and Asthma European Network (GA2LEN) chamber for trials in allergy: Innovation of a mobile allergen exposure chamber","volume":"139","author":"Zuberbier","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1111\/all.13933","article-title":"Development and validation of an Allergen Challenge Theater for grass and ragweed","volume":"74","author":"Yang","year":"2019","journal-title":"Allergy"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40629-017-0040-0","article-title":"Technical specifications of the Global Allergy and Asthma European Network (GA2LEN) chamber: A novel mobile allergen exposure chamber","volume":"26","author":"Voegler","year":"2017","journal-title":"Allergo J. Int."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2500\/aap.2012.33.3579","article-title":"Provocation of nonallergic rhinitis subjects in response to simulated weather conditions using an environmental exposure chamber model","volume":"33","author":"Bernstein","year":"2012","journal-title":"Allergy Asthma Proc."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.anai.2021.06.015","article-title":"Environmental exposure unit simulates natural seasonal birch pollen exposures while maximizing change in allergic symptoms","volume":"127","author":"Ellis","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/all.13606","article-title":"A birch sublingual allergy immunotherapy tablet reduces rhinoconjunctivitis symptoms when exposed to birch and oak and induces IgG4 to allergens from all trees in the birch homologous group","volume":"74","author":"Couroux","year":"2019","journal-title":"Allergy"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e12053","DOI":"10.1002\/clt2.12053","article-title":"Birch allergen challenges in allergic conjunctivitis using standard conjunctival allergen challenge and environmental exposure chamber","volume":"11","author":"Gherasim","year":"2021","journal-title":"Clin. Transl. Allergy"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/cea.14130","article-title":"Efficacy of N-acetyl aspartyl glutamic acid versus fluorometholone for treating allergic conjunctivitis in an environmental exposure chamber","volume":"52","author":"Gherasim","year":"2022","journal-title":"Clin. Exp. Allergy"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2500\/aap.2022.43.210097","article-title":"Birch-naive, oak-allergic subjects\u2019 response to birch pollen in an environmental chamber","volume":"43","author":"Ramirez","year":"2022","journal-title":"Allergy Asthma Proc."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/cea.13511","article-title":"Efficacy of air cleaners in asthmatics allergic to cat in ALYATEC\u00ae environmental exposure chamber","volume":"50","author":"Gherasim","year":"2020","journal-title":"Clin. Exp. Allergy"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"70","DOI":"10.5414\/ALX02473E","article-title":"Individual wearable air purifier protects against pollen, house dust mite, and cat allergens: Report from an allergen exposure chamber","volume":"8","author":"Bergmann","year":"2024","journal-title":"Allergol. Select"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jaci.2010.09.043","article-title":"Effects of omalizumab on changes in pulmonary function induced by controlled cat room challenge","volume":"127","author":"Corren","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e12277","DOI":"10.1002\/clt2.12277","article-title":"Barrier-forming, drug-free nasal spray reduces allergic symptoms induced by house dust mite allergen","volume":"13","author":"Couroux","year":"2023","journal-title":"Clin. Transl. Allergy"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Hossenbaccus, L., Linton, S., Thiele, J., Steacy, L., Walker, T., Malone, C., and Ellis, A.K. (2022). Biologic responses to house dust mite exposure in the Environmental Exposure Unit. Front. Allergy, 2.","DOI":"10.3389\/falgy.2021.807208"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1517\/14656560902758368","article-title":"Bepotastine besilate OD tablets suppress nasal symptoms caused by Japanese cedar pollen exposure in an artificial exposure chamber (OHIO Chamber)","volume":"10","author":"Hashiguchi","year":"2009","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.anai.2016.05.015","article-title":"Persistent nasal symptoms and mediator release after continuous pollen exposure in an environmental challenge chamber","volume":"117","author":"Okuma","year":"2016","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2332\/allergolint.10-OA-0264","article-title":"Evaluating the effects of testing period on pollinosis symptoms using an allergen challenge chamber","volume":"60","author":"Yuki","year":"2011","journal-title":"Allergol. Int."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13223-017-0227-4","article-title":"Onset of action for loratadine tablets for the symptomatic control of seasonal allergic rhinitis in adults challenged with ragweed pollen in the Environmental Exposure Unit: A post hoc analysis of total symptom score","volume":"14","author":"Tenn","year":"2018","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1710-1492-9-16","article-title":"A four-way, double-blind, randomized, placebo-controlled study to determine the efficacy and speed of azelastine nasal spray, versus loratadine, and cetirizine in adult subjects with allergen-induced seasonal allergic rhinitis","volume":"9","author":"Ellis","year":"2013","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1081-1206(10)63104-3","article-title":"Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis","volume":"79","author":"Day","year":"1997","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S1081-1206(10)62260-0","article-title":"Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: Confirmation of a test system","volume":"87","author":"Day","year":"2001","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1081-1206(10)61909-6","article-title":"Onset of action, efficacy, and safety of fexofenadine 60 mg\/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit","volume":"89","author":"Berkowitz","year":"2002","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.clinthera.2006.10.023","article-title":"Onset of action of fexofenadine hydrochloride 60 mg\/pseudoephedrine hydrochloride 120 mg in subjects aged 12 years with moderate to severe seasonal allergic rhinitis: A pooled analysis of two single-dose, randomized, double-blind, placebo-controlled allergen exposure unit studies","volume":"28","author":"Berkowitz","year":"2006","journal-title":"Clin. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S1081-1206(10)63483-7","article-title":"Efficacy of immunotherapy to ragweed antigen tested by controlled antigen exposure","volume":"77","author":"Donovan","year":"1996","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.anai.2016.07.018","article-title":"Efficacy of the novel nasal steroid S0597 tested in an environmental exposure unit","volume":"117","author":"Ellis","year":"2016","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1081-1206(10)63062-1","article-title":"Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit","volume":"79","author":"Day","year":"1997","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/OPTH.S345324","article-title":"Reproxalap improves signs and symptoms of allergic conjunctivitis in an allergen chamber: A real-world model of allergen exposure","volume":"16","author":"Clark","year":"2022","journal-title":"Clin. Ophthalmol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s40629-021-00180-8","article-title":"Face masks suitable for preventing COVID-19 and pollen allergy. A study in the exposure chamber","volume":"30","author":"Bergmann","year":"2021","journal-title":"Allergo J. Int."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.anai.2017.01.018","article-title":"Specificity and reproducibility of nasal biomarkers in patients with allergic rhinitis after allergen challenge chamber exposure","volume":"118","author":"Badorrek","year":"2017","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1111\/cea.12977","article-title":"Dose-response relationship of a new Timothy grass pollen allergoid in comparison with a 6-grass pollen allergoid","volume":"47","author":"Pfaar","year":"2017","journal-title":"Clin. Exp. Allergy"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.anai.2010.12.018","article-title":"Anti-allergic drug testing in an environmental challenge chamber is suitable both in and out of the relevant pollen season","volume":"106","author":"Badorrek","year":"2011","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.anai.2015.07.016","article-title":"Efficacy and safety of a novel nasal steroid, S0597, in patients with seasonal allergic rhinitis","volume":"115","author":"Badorrek","year":"2015","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_83","first-page":"1077","article-title":"Efficacy and tolerability of astemizole-D and Loratadine-D during prolonged, controlled allergen challenge in the Vienna Challenge Chamber","volume":"46","author":"Horak","year":"1996","journal-title":"Arzneimittelforschung"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1398-9995.2010.02473.x","article-title":"The allergen challenge chamber: A valuable tool for optimizing the clinical development of pollen immunotherapy","volume":"66","author":"Devillier","year":"2011","journal-title":"Allergy"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/all.12373","article-title":"Magnitude of efficacy measurements in grass allergy immunotherapy trials is highly dependent on pollen exposure","volume":"69","author":"Durham","year":"2014","journal-title":"Allergy"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.anai.2019.03.007","article-title":"Clinical standardization of two controlled allergen challenge facilities: The Environmental Exposure Unit and the Biogenics Research Chamber","volume":"122","author":"Ellis","year":"2019","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"(2012). immunotherapy studies shows increased clinical efficacy in highly symptomatic patients. Allergy, 67, 321\u2013327.","DOI":"10.1111\/j.1398-9995.2011.02759.x"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.jaci.2014.12.1911","article-title":"Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber","volume":"135","author":"Nolte","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1177\/030006059202000507","article-title":"Onset and duration of the effects of three antihistamines in current use\u2014Astemizole, loratadine and terfenadine forte--studied during prolonged, controlled allergen challenges in volunteers","volume":"20","author":"Horak","year":"1992","journal-title":"J. Int. Med. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1185\/030079904125003700","article-title":"A direct comparison of the efficacy of antihistamines in SAR and PAR: Randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit\u2014The Vienna Challenge Chamber (VCC)","volume":"20","author":"Zieglmayer","year":"2004","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Davis, A., Linton, S., Hossenbaccus, L., Thiele, J., Botting, H., Walker, T., Steacy, L.M., and Ellis, A.K. (2024). Analyzing Phenotypes Post-Exposure in Allergic Rhinitis (APPEAR) in the Environmental Exposure Unit (EEU). Ann. Allergy Asthma Immunol, online ahead of print.","DOI":"10.1016\/j.anai.2024.11.002"},{"key":"ref_92","unstructured":"European Medicines Agency (2024, October 23). Committee for Medicinal Products for Human Use (CHMP): Guideline on the Clinical Development of Products for Specific Immunotherapy for The Treatment of Allergic Diseases (CHMP\/EWP\/18504\/2006). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-clinical-development-products-specific-immunotherapy-treatment-allergic-diseases_en.pdf."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/all.12383","article-title":"Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: An EAACI Position Paper","volume":"69","author":"Pfaar","year":"2014","journal-title":"Allergy"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1111\/j.1365-2222.2010.03498.x","article-title":"Diagnostic value of outcome measures following allergen exposure in an environmental challenge chamber compared with natural conditions","volume":"40","author":"Hohlfeld","year":"2010","journal-title":"Clin. Exp. Allergy"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/all.13138","article-title":"Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: An EAACI Position Paper","volume":"72","author":"Shamji","year":"2017","journal-title":"Allergy"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1111\/all.15817","article-title":"Standardization of clinical outcomes used in allergen immunotherapy in allergic asthma: An EAACI position paper","volume":"78","author":"Kappen","year":"2023","journal-title":"Allergy"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.jaci.2022.06.025","article-title":"REGN1908\/1909 prevented cat allergen-induced early asthmatic responses in an environmental exposure unit","volume":"150","author":"Gherasim","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1398-9995.1997.tb02153.x","article-title":"Exposure chamber for allergen challenge. A placebo-controlled, double-blind trial in house-dust-mite asthma","volume":"52","author":"Mosbech","year":"1997","journal-title":"Allergy"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/02770903.2018.1563902","article-title":"Validation of Strasbourg environmental exposure chamber (EEC) ALYATEC\u00ae in mite allergic subjects with asthma","volume":"57","author":"Khayath","year":"2020","journal-title":"J. Asthma"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.anai.2021.04.012","article-title":"Comparing the nasal allergen challenge and environmental exposure unit models of allergic rhinitis","volume":"127","author":"Ramchandani","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"100801","DOI":"10.1016\/j.waojou.2023.100801","article-title":"Birch-induced allergic rhinitis: Results of exposure during nasal allergen challenge, environmental chamber, and pollen season","volume":"16","author":"Gherasim","year":"2023","journal-title":"World Allergy Organ J."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/1744666X.2021.1905523","article-title":"The use of nasal allergen vs allergen exposure chambers to evaluate allergen immunotherapy","volume":"17","author":"Hossenbaccus","year":"2021","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/all.13416","article-title":"EAACI Position paper on the standardization of nasal allergen challenges","volume":"73","author":"Vent","year":"2018","journal-title":"Allergy"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.anai.2019.04.003","article-title":"Comparison of allergic rhinitis outcomes of the environmental exposure unit and nasal allergen challenge model","volume":"123","author":"Tenn","year":"2019","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/ACI.0000000000000929","article-title":"The use of environmental exposure chambers in studies related to ocular surface effects","volume":"23","author":"Gherasim","year":"2023","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jfo.2020.07.001","article-title":"Int\u00e9r\u00eat des chambres d\u2019exposition environnementale dans l\u2019\u00e9valuation des conjonctivites allergiques [Interest of environmental exposure chambers in the evaluation of allergic conjunctivitis]","volume":"43","author":"Ehret","year":"2020","journal-title":"J. Fr. Ophtalmol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e12274","DOI":"10.1002\/clt2.12274","article-title":"The holo beta-lactoglobulin lozenge reduces symptoms in cat allergy\u2014Evaluation in an allergen exposure chamber and by titrated nasal allergen challenge","volume":"13","author":"Bergmann","year":"2023","journal-title":"Clin. Transl. Allergy"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jaci.2012.05.032","article-title":"Correlation between a pollen challenge chamber and a natural allergen exposure study design for eliciting ocular and nasal symptoms: Early evidence supporting a paradigm shift in drug investigation?","volume":"130","author":"Bernstein","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.anai.2016.10.023","article-title":"Redness response phenotypes of allergic conjunctivitis in an allergen challenge chamber","volume":"118","author":"Jacobs","year":"2017","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.rmr.2018.01.005","article-title":"Les chambres d\u2019exposition environnementale (CEE): Un nouvel outil dans la recherche acad\u00e9mique et industrielle [Environmental exposure chambers (EEC): A novel tool for pathophysiological and pharmaceutical research]","volume":"35","author":"Khayath","year":"2018","journal-title":"Rev. Mal. Respir."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/ACI.0000000000000808","article-title":"Update on the use of allergen challenge chambers in immunotherapy: Clinical implications","volume":"22","author":"Zieglmayer","year":"2022","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13601-020-00336-9","article-title":"Allergen exposure chambers: Implementation in clinical trials in allergen immunotherapy","volume":"10","author":"Pfaar","year":"2020","journal-title":"Clin. Transl. Allergy"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/23\/7268\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:42:35Z","timestamp":1760114555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/23\/7268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":112,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["jcm13237268"],"URL":"https:\/\/doi.org\/10.3390\/jcm13237268","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]}}}